ImmunityBio short interest was 37.06% of the float on April 15th, according to new data we received from Benzinga. Short interest totaled 140,326,066 shares, which was an increase of 3.53% from March 31st.
It is estimated that it would take 9.54 days for short sellers to buy back their shares, with current trading volumes.
ImmunityBio Hedge Fund Activity
We have seen 166 institutional investors add shares of ImmunityBio stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEIGHTS CAPITAL MANAGEMENT, INC removed 6,565,709 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $13,000,103
- BLACKROCK, INC. added 5,790,256 shares (+29.2%) to their portfolio in Q4 2025, for an estimated $11,464,706
- STATE STREET CORP added 5,139,890 shares (+45.4%) to their portfolio in Q4 2025, for an estimated $10,176,982
- VANGUARD GROUP INC added 5,122,052 shares (+18.5%) to their portfolio in Q4 2025, for an estimated $10,141,662
- CITIGROUP INC removed 2,271,488 shares (-95.4%) from their portfolio in Q4 2025, for an estimated $4,497,546
- TWO SIGMA INVESTMENTS, LP added 2,109,983 shares (+80.9%) to their portfolio in Q4 2025, for an estimated $4,177,766
- WOODLINE PARTNERS LP removed 1,851,185 shares (-34.9%) from their portfolio in Q4 2025, for an estimated $3,665,346
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
ImmunityBio Insider Trading Activity
ImmunityBio insiders have traded $IBRX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $IBRX stock by insiders over the last 6 months:
- BARRY J. SIMON has made 0 purchases and 5 sales selling 401,967 shares for an estimated $3,778,685.
- CHRISTOBEL SELECKY has made 0 purchases and 3 sales selling 100,000 shares for an estimated $687,650.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
ImmunityBio Analyst Ratings
Wall Street analysts have issued reports on $IBRX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/23/2026
- Piper Sandler issued a "Overweight" rating on 01/20/2026
- D. Boral Capital issued a "Buy" rating on 01/20/2026
To track analyst ratings and price targets for ImmunityBio, check out Quiver Quantitative's $IBRX forecast page.
ImmunityBio Price Targets
Multiple analysts have issued price targets for $IBRX recently. We have seen 7 analysts offer price targets for $IBRX in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $23.0 on 04/21/2026
- Jeet Mukherjee from BTIG set a target price of $13.0 on 03/12/2026
- Edward Tenthoff from Piper Sandler set a target price of $12.0 on 03/04/2026
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $15.0 on 02/23/2026
- Kelly Shi from Jefferies set a target price of $9.0 on 12/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
